Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 10/20 | 0.50 |
| ▸ | DHFR | P00374 | 3/20 | 0.45 |
| ▸ | TYMS | P04818 | 2/20 | 0.45 |
| ▸ | ATIC | P31939 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16116814 | 0.92 | NOS1 (0.47) | NOS1DHFRTYMSATICAKR1B1 | |
| SCHEMBL17324339 | 0.86 | NOS1 (0.53) | NOS1DHFRTYMSAKR1B1KDM4E | |
| SCHEMBL9315958 | 0.85 | NOS1 (0.52) | NOS1DHFRTYMSAKR1B1KDM4E | |
| SCHEMBL5006245 | 0.85 | NOS1 (0.52) | NOS1DHFRTYMSATICAKR1B1 | |
| SCHEMBL30097253 | 0.85 | NOS1 (0.52) | NOS1DHFRTYMSATICAKR1B1 | |
| SCHEMBL13662277 | 0.84 | NOS1 (0.50) | NOS1DHFRTYMSATICAKR1B1 | |
| SCHEMBL23057582 | 0.83 | TYMS (0.70) | DHFRTYMSATICAKR1B1KDM4E | |
| SCHEMBL1547431 | 0.83 | TYMS (0.70) | DHFRTYMSATICAKR1B1KDM4E | |
| SCHEMBL29563972 | 0.83 | TYMS (0.70) | DHFRTYMSATICAKR1B1KDM4E | |
| SCHEMBL4607260 | 0.82 | DHFR (0.51) | DHFRTYMSATICKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566047-B2 | Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof | TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (JP) | 2023-01-31 | — | — | US | disclosed |
| US-20190177370-A1 | PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PRODRUG THEREOF | TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (JP) | 2019-06-13 | — | — | US | disclosed |
| US-20170128599-A1 | FOLATE-CONJUGATES AND CORRESPONDING METAL-CHELATE COMPLEXES FOR USE IN DIAGNOSTIC IMAGING AND RADIOTHERAPY | Merck & Cie (CH) | 2017-05-11 | — | — | US | disclosed |
| WO-2014149073-A1 | METHODS OF MANUFACTURE AND SYNTHESIS OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR TARGETED IMAGING OF TUMORS | ON TARGET LABORATORIES LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20100143249-A1 | FOLATE-CONJUGATES AND CORRESPONDING METAL-CHELATE COMPLEXES FOR USE IN DIAGNOSTIC IMAGING AND RADIOTHERAPY | MERCK EPROVA AG (CH) | 2010-06-10 | — | — | US | disclosed |
| EP-2146995-A1 | FOLATE-CONJUGATES AND CORRESPONDING METAL-CHELATE COMPLEXES FOR USE IN DIAGNOSTIC IMAGING AND RADIOTHERAPY | Merck Eprova AG (CH) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125618-A1 | FOLATE-CONJUGATES AND CORRESPONDING METAL-CHELATE COMPLEXES FOR USE IN DIAGNOSTIC IMAGING AND RADIOTHERAPY | MERCK EPROVA AG (CH) | 2008-10-23 | — | — | WO | disclosed |
| US-5498601-A | RGD SEQUENCE | NIPPON STEEL CORPORATION (JP) | 1996-03-12 | — | — | US | disclosed |
| EP-0628571-A1 | NOVEL PEPTIDE, AND ANTITHROMBOTIC AGENT, ANTICOAGULANT FOR EXTRACORPOREAL CIRCULATION, CELL FUSION INHIBITOR, CANCER METASTASIS INHIBITOR, PROTECTIVE FOR PLATELET PREPARATION FOR TRANSFUSION AND PACK OF PLATELET PREPARATION FOR TRANSFUSION | NIPPON STEEL CORPORATION (JP) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177370-A1 | PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PRODRUG THEREOF | MYOF, MSTN, VIP | NOS1 895/4885DHFR 1765/4885TYMS 1929/4885 |
| US-20100143249-A1 | FOLATE-CONJUGATES AND CORRESPONDING METAL-CHELATE COMPLEXES FOR USE IN DIAGNOSTIC IMAGING AND RADIOTHERAPY | FOLR1, FOLR2, SLC19A1 | NOS1 2682/4885DHFR 4/4885TYMS 34/4885 |
| US-11566047-B2 | Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof | MYOF, MSTN, VIP | NOS1 895/4885DHFR 1765/4885TYMS 1929/4885 |
| US-20170128599-A1 | FOLATE-CONJUGATES AND CORRESPONDING METAL-CHELATE COMPLEXES FOR USE IN DIAGNOSTIC IMAGING AND RADIOTHERAPY | FOLR1, FOLR2, SLC19A1 | NOS1 2682/4885DHFR 4/4885TYMS 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.